GHRH (1–44) vs Sermorelin
Both GHRH (1–44) and Sermorelin are used for growth-hormone. Here's how their evidence, dosing, and regulatory status actually compare.
GHRH (1–44)
Evidence AGrowth Hormone Releasing Hormone, full sequence
The full 44-amino-acid GHRH sequence. The natural pituitary stimulus for GH release. Largely supplanted in clinical use by sermorelin/tesamorelin but remains a research and diagnostic tool.
View full GHRH (1–44) profile →Sermorelin
Evidence B+Sermorelin Acetate (GHRH 1-29)
The original synthetic GHRH(1–29) and the most accessible GH-stimulating peptide for age-related hormone decline. Stimulates the body's own pulsatile GH release rather than replacing it.
View full Sermorelin profile →Side-by-Side
| Attribute | GHRH (1–44) | Sermorelin |
|---|---|---|
| Evidence Grade | A | B+ |
| FDA Status | FDA-approved (Geref) historically as diagnostic GH stimulant; current US availability limited | FDA-approved (1990) for pediatric growth hormone deficiency; off-label adult use via compounding pharmacies |
| Typical Dose | 1 mcg/kg IV (diagnostic test) | 200–500 mcg before bed (subcutaneous) |
| Clinics Indexed | 22 | 220 |
| Categories | growth-hormone | growth-hormone, anti-aging |
Key reported benefits — GHRH (1–44)
- ✓Endogenous GH stimulation
- ✓Diagnostic GH testing
Key reported benefits — Sermorelin
- ✓Natural GH release
- ✓Improved sleep
- ✓Lean body mass
- ✓Recovery
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.